Sodium-glucose co-transporter-2 inhibitors (SGLT-2 inhibitors) are a new group of antidiabetic drugs which are also beneficial in the treatment of cardiovascular diseases in both diabetic and non-diabetic patients. This evidence concerns the gene SLC5A2 and cardiovascular disorder.